

Vera Bril

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5174605/publications.pdf>

Version: 2024-02-01

279
papers

16,676
citations

26630

56
h-index

18647

119
g-index

281
all docs

281
docs citations

281
times ranked

10351
citing authors

#	ARTICLE	IF	CITATIONS
1	Canadian Guidelines for Hereditary Transthyretin Amyloidosis Polyneuropathy Management. Canadian Journal of Neurological Sciences, 2022, 49, 7-18.	0.5	9
2	Myasthenia gravis in pregnancy: Systematic review and case series. Obstetric Medicine, 2022, 15, 108-117.	1.1	16
3	The association between physical activity time and neuropathy in longstanding type 1 diabetes: A cross-sectional analysis of the Canadian study of longevity in type 1 diabetes. Journal of Diabetes and Its Complications, 2022, 36, 108134.	2.3	5
4	Pilot study of a novel transmembranous electromyography device for assessment of oral cavity and oropharyngeal muscles. Muscle and Nerve, 2022, 65, 303-310.	2.2	2
5	Advances and ongoing research in the treatment of autoimmune neuromuscular junction disorders. Lancet Neurology, The, 2022, 21, 189-202.	10.2	41
6	Electrodiagnostic evaluation in diabetic neuropathy. , 2022, , 35-45.		1
7	THE SENSITIVITY AND SPECIFICITY OF SPLIT HAND INDEX USING MUSCLE SONOGRAPHY. Canadian Journal of Neurological Sciences, 2022, , 1-16.	0.5	0
8	Orthostatic blood pressure changes and diabetes duration. Journal of Diabetes and Its Complications, 2022, 36, 108169.	2.3	2
9	Analysis of relapse by inflammatory Raschâ€built overall disability scale status in the <sc>PATH</sc> study of subcutaneous immunoglobulin in chronic inflammatory demyelinating polyneuropathy. Journal of the Peripheral Nervous System, 2022, 27, 159-165.	3.1	3
10	Clinical profile and multidisciplinary needs of patients with neuromuscular disorders transitioning from paediatric to adult care. Neuromuscular Disorders, 2022, 32, 206-212.	0.6	0
11	Polyneuropathy Quality Measurement Set. Neurology, 2022, 98, 22-30.	1.1	0
12	Oral and Topical Treatment of Painful Diabetic Polyneuropathy: Practice Guideline Update Summary. Neurology, 2022, 98, 31-43.	1.1	64
13	Temporal Dispersion and Duration of the Distal Compound Muscle Action Potential Do Not Distinguish Diabetic Sensorimotor Polyneuropathy From Chronic Inflammatory Demyelinating Polyneuropathy. Frontiers in Neurology, 2022, 13, 872762.	2.4	1
14	Pharmacotherapy of Generalized Myasthenia Gravis with Special Emphasis on Newer Biologicals. Drugs, 2022, 82, 865-887.	10.9	36
15	An update on the use of immunoglobulins as treatment for myasthenia gravis. Expert Review of Clinical Immunology, 2022, 18, 703-715.	3.0	2
16	Retrospective study on the safety of <sc>COVID</sc>-19 vaccination in myasthenia gravis. Muscle and Nerve, 2022, 66, 558-561.	2.2	10
17	Efficacy and Safety of Rozanolixizumab in Moderate to Severe Generalized Myasthenia Gravis. Neurology, 2021, 96, e853-e865.	1.1	97
18	Electrophysiological testing in chronic inflammatory demyelinating polyneuropathy patients treated with subcutaneous immunoglobulin: The Polyneuropathy And Treatment with Hizentra (PATH) study. Clinical Neurophysiology, 2021, 132, 226-231.	1.5	4

#	ARTICLE	IF	CITATIONS
19	Baseline omega-3 level is associated with nerve regeneration following 12-months of omega-3 nutrition therapy in patients with type 1 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2021, 35, 107798.	2.3	10
20	Fasciculation frequency at the biceps <scp>brachii</scp> and brachialis muscles is associated with <scp>amyotrophic lateral sclerosis</scp> disease burden and activity. <i>Muscle and Nerve</i> , 2021, 63, 204-208.	2.2	7
21	Performance of different criteria for refractory myasthenia gravis. <i>European Journal of Neurology</i> , 2021, 28, 1375-1384.	3.3	9
22	Chronic immunoglobulin maintenance therapy in myasthenia gravis. <i>European Journal of Neurology</i> , 2021, 28, 639-646.	3.3	27
23	Myasthenia Gravis and Pregnancy: Toronto Specialty Center Experience. <i>Canadian Journal of Neurological Sciences</i> , 2021, , 1-5.	0.5	7
24	The complex association between pain and neuropathy. <i>Muscle and Nerve</i> , 2021, 63, 538-545.	2.2	0
25	Thymoma pathology and myasthenia gravis outcomes. <i>Muscle and Nerve</i> , 2021, 63, 868-873.	2.2	11
26	Practical Aspects of Transitioning from Intravenous to Subcutaneous Immunoglobulin Therapy in Neuromuscular Disorders. <i>Canadian Journal of Neurological Sciences</i> , 2021, , 1-7.	0.5	2
27	Treatment Approaches for Atypical CIDP. <i>Frontiers in Neurology</i> , 2021, 12, 653734.	2.4	9
28	Telephone consultation for myasthenia gravis care during the COVID â€19 pandemic: Assessment of a novel virtual myasthenia gravis index. <i>Muscle and Nerve</i> , 2021, 63, 831-836.	2.2	9
29	Emerging drugs for the treatment of myasthenia gravis. <i>Expert Opinion on Emerging Drugs</i> , 2021, 26, 259-270.	2.4	6
30	Corneal Confocal Microscopy Predicts the Development of Diabetic Neuropathy: A Longitudinal Diagnostic Multinational Consortium Study. <i>Diabetes Care</i> , 2021, 44, 2107-2114.	8.6	28
31	Clinical profile and impact of comorbidities in patients with veryâ€lateâ€onset myasthenia gravis. <i>Muscle and Nerve</i> , 2021, 64, 462-466.	2.2	13
32	Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial. <i>Lancet Neurology</i> , The, 2021, 20, 526-536.	10.2	194
33	Analgesic effect of perineural local anesthetics, steroids, and conventional medical management for trauma and compression-related peripheral neuropathic pain: a retrospective cohort study. <i>Pain Reports</i> , 2021, 6, e945.	2.7	2
34	Pharmacometric analysis linking immunoglobulin exposure to clinical efficacy outcomes in chronic inflammatory demyelinating polyneuropathy. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2021, 10, 839-850.	2.5	2
35	Electrophysiological predictors of response to subcutaneous immunoglobulin therapy in chronic inflammatory demyelinating polyneuropathy. <i>Clinical Neurophysiology</i> , 2021, 132, 2184-2190.	1.5	3
36	Omega-3 Nutrition Therapy for the Treatment of Diabetic Sensorimotor Polyneuropathy. <i>Current Diabetes Reviews</i> , 2021, 17, .	1.3	1

#	ARTICLE	IF	CITATIONS
37	Patient-reported outcomes with subcutaneous immunoglobulin in chronic inflammatory demyelinating polyneuropathy: the PATH study. <i>European Journal of Neurology</i> , 2020, 27, 196-203.	3.3	11
38	Chronic stress, depression and personality type in patients with myasthenia gravis. <i>European Journal of Neurology</i> , 2020, 27, 204-209.	3.3	14
39	Quantitative sonographic evaluation of muscle thickness and fasciculation prevalence in healthy subjects. <i>Muscle and Nerve</i> , 2020, 61, 234-238.	2.2	13
40	The utility of a single simple question in the evaluation of patients with nondiabetic polyneuropathy. <i>Muscle and Nerve</i> , 2020, 61, 526-529.	2.2	4
41	Important advances in neuromuscular research in 2019. <i>Lancet Neurology</i> , The, 2020, 19, 14-16.	10.2	1
42	Placebo effect in chronic inflammatory demyelinating polyneuropathy: The <sc>PATH</sc> study and a systematic review. <i>Journal of the Peripheral Nervous System</i> , 2020, 25, 230-237.	3.1	15
43	Patient-acceptable symptom states in myasthenia gravis. <i>Neurology</i> , 2020, 95, e1617-e1628.	1.1	33
44	Quality of life in patients with neurofibromatosis type 1 and 2 in Canada. <i>Neuro-Oncology Advances</i> , 2020, 2, i141-i149.	0.7	18
45	Superiority of sonographic evaluation of contracted versus relaxed muscle thickness in motor neuron diseases. <i>Clinical Neurophysiology</i> , 2020, 131, 1480-1486.	1.5	10
46	Comparison of the single simple question and the patient acceptable symptom state in myasthenia gravis. <i>European Journal of Neurology</i> , 2020, 27, 2286-2291.	3.3	11
47	New insights into very-late-onset myasthenia gravis. <i>Nature Reviews Neurology</i> , 2020, 16, 299-300.	10.1	8
48	Prospective study of stress, depression and personality in myasthenia gravis relapses. <i>BMC Neurology</i> , 2020, 20, 261.	1.8	9
49	Novel Treatments in Myasthenia Gravis. <i>Frontiers in Neurology</i> , 2020, 11, 538.	2.4	54
50	Electrophysiological Responsiveness to Long-Term Therapy in Chronic Inflammatory Demyelinating Polyneuropathy: Case Report. <i>Case Reports in Neurology</i> , 2020, 12, 40-44.	0.7	3
51	Rapid Corneal Nerve Fiber Loss: A Marker of Diabetic Neuropathy Onset and Progression. <i>Diabetes Care</i> , 2020, 43, 1829-1835.	8.6	40
52	Myasthenia Gravis Impairment Index: Sensitivity for Change in Generalized Muscle Weakness. <i>Journal of Neuromuscular Diseases</i> , 2020, 7, 297-300.	2.6	8
53	Split-hand phenomenon in motor neuron diseases: Sonographic assesment of muscle thickness. <i>Clinical Neurophysiology</i> , 2020, 131, 1721-1725.	1.5	11
54	Congenital myasthenic syndrome-associated agrin variants affect clustering of acetylcholine receptors in a domain-specific manner. <i>JCI Insight</i> , 2020, 5, .	5.0	15

#	ARTICLE	IF	CITATIONS
55	Randomized, controlled crossover study of IVIg for demyelinating polyneuropathy and diabetes. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2019, 6, .	6.0	4
56	Sex differences in neuropathy & neuropathic pain: A brief report from the Phase 2 Canadian Study of Longevity in Type 1 Diabetes. <i>Journal of Diabetes and Its Complications</i> , 2019, 33, 107397.	2.3	8
57	Baseline Decrement in Patients with Mild Myasthenia Gravis Predicts Immunomodulation Treatment. <i>Canadian Journal of Neurological Sciences</i> , 2019, 46, 762-766.	0.5	1
58	European Federation of Neurological Societies cutoff values significantly reduce creatine kinase sensitivity for diagnosing neuromuscular disorders. <i>Muscle and Nerve</i> , 2019, 60, 748-752.	2.2	2
59	Current pharmacotherapeutic options for myasthenia gravis. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 2295-2303.	1.8	20
60	Evidence of smallâ€fiber neuropathy in neurofibromatosis type 1. <i>Muscle and Nerve</i> , 2019, 60, 673-678.	2.2	9
61	Muscle thickness measured by ultrasound is reduced in neuromuscular disorders and correlates with clinical and electrophysiological findings. <i>Muscle and Nerve</i> , 2019, 60, 687-692.	2.2	20
62	A Phase 3 Multicenter, Prospective, Open-Label Efficacy and Safety Study of Immune Globulin (Human) 10% Caprylate/Chromatography Purified in Patients with Myasthenia Gravis Exacerbations. <i>European Neurology</i> , 2019, 81, 223-230.	1.4	23
63	Long-term safety and efficacy of subcutaneous immunoglobulin IgPro20 in CIDP. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2019, 6, e590.	6.0	37
64	Qualitative, Patient-Centered Assessment of Muscle Cramp Impact and Severity. <i>Canadian Journal of Neurological Sciences</i> , 2019, 46, 735-741.	0.5	4
65	Efficacy and safety of IVIG in CIDP: Combined data of the PRIMA and PATH studies. <i>Journal of the Peripheral Nervous System</i> , 2019, 24, 48-55.	3.1	17
66	Restabilization treatment after intravenous immunoglobulin withdrawal in chronic inflammatory demyelinating polyneuropathy: Results from the preâ€randomization phase of the Polyneuropathy And Treatment with Hizentra study. <i>Journal of the Peripheral Nervous System</i> , 2019, 24, 72-79.	3.1	13
67	Elevated plasma cyclic guanosine monophosphate may explain greater efferent arteriolar tone in adults with longstanding type 1 diabetes: A brief report. <i>Journal of Diabetes and Its Complications</i> , 2019, 33, 547-549.	2.3	1
68	Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis. <i>Neurology</i> , 2019, 92, e2661-e2673.	1.1	169
69	Acute Intermittent Porphyria: A Report of 3 Cases with Neuropathy. <i>Case Reports in Neurology</i> , 2019, 11, 32-36.	0.7	10
70	Estimating GFR by Serum Creatinine, Cystatin C, and Î²2-Microglobulin in Older Adults: Results From the Canadian Study of Longevity in Type 1 Diabetes. <i>Kidney International Reports</i> , 2019, 4, 786-796.	0.8	12
71	Risk factors for diabetic kidney disease in adults with longstanding type 1 diabetes: results from the Canadian Study of Longevity in Diabetes. <i>Renal Failure</i> , 2019, 41, 427-433.	2.1	4
72	Diabetic neuropathy. <i>Nature Reviews Disease Primers</i> , 2019, 5, 41.	30.5	692

#	ARTICLE	IF	CITATIONS
73	Uric Acid Levels Correlate with Sensory Nerve Function in Healthy Subjects. Canadian Journal of Neurological Sciences, 2019, 46, 337-341.	0.5	4
74	Renal Hemodynamic Function and RAAS Activation Over the Natural History of Type 1 Diabetes. American Journal of Kidney Diseases, 2019, 73, 786-796.	1.9	15
75	Association between uric acid, renal haemodynamics and arterial stiffness over the natural history of type 1 diabetes. Diabetes, Obesity and Metabolism, 2019, 21, 1388-1398.	4.4	12
76	Ultrasound in Multifocal Motor Neuropathy: Clinical and Electrophysiological Correlations. Journal of Clinical Neuromuscular Disease, 2019, 20, 165-172.	0.7	1
77	Bone mineral density in patients with longstanding type 1 diabetes: Results from the Canadian Study of Longevity in Type 1 Diabetes. Journal of Diabetes and Its Complications, 2019, 33, 1073-24.	2.3	21
78	Ultrasound-Assisted Lumbar Puncture in a Neuromuscular Clinic has a High Success Rate and Less Pain. Canadian Journal of Neurological Sciences, 2019, 46, 79-82.	0.5	6
79	The relationships between markers of tubular injury and intrarenal haemodynamic function in adults with and without type 1 diabetes: Results from the Canadian Study of Longevity in Type 1 Diabetes. Diabetes, Obesity and Metabolism, 2019, 21, 575-583.	4.4	15
80	EQâ€5Dâ€5L and SFâ€6D health utility index scores in patients with myasthenia gravis. European Journal of Neurology, 2019, 26, 452-459.	3.3	12
81	Retinopathy and RAAS Activation: Results From the Canadian Study of Longevity in Type 1 Diabetes. Diabetes Care, 2019, 42, 273-280.	8.6	16
82	Laboratory Abnormalities in Polyneuropathy and Electrophysiological Correlations. Canadian Journal of Neurological Sciences, 2018, 45, 346-349.	0.5	3
83	Sex differences in neuropathic pain intensity in diabetes. Journal of the Neurological Sciences, 2018, 388, 103-106.	0.6	38
84	Randomized study of adjunctive belimumab in participants with generalized myasthenia gravis. Neurology, 2018, 90, e1425-e1434.	1.1	86
85	Muscle biopsy technical safety and quality using a self-contained, vacuum-assisted biopsy technique. Neuromuscular Disorders, 2018, 28, 450-453.	0.6	14
86	Adiposity Impacts Intrarenal Hemodynamic Function in Adults With Long-standing Type 1 Diabetes With and Without Diabetic Nephropathy: Results From the Canadian Study of Longevity in Type 1 Diabetes. Diabetes Care, 2018, 41, 831-839.	8.6	13
87	Fatigue is a relevant outcome in patients with myasthenia gravis. Muscle and Nerve, 2018, 58, 197-203.	2.2	33
88	Nerve function varies with hemoglobin A1c in controls and type 2 diabetes. Journal of Diabetes and Its Complications, 2018, 32, 424-428.	2.3	5
89	High frequency of MGUS in DSP. Muscle and Nerve, 2018, 57, 1018-1021.	2.2	0
90	The utility of a single simple question in the evaluation of patients with myasthenia gravis. Muscle and Nerve, 2018, 57, 240-244.	2.2	27

#	ARTICLE	IF	CITATIONS
91	Cramps frequency and severity are correlated with small and large nerve fiber measures in type 1 diabetes. <i>Clinical Neurophysiology</i> , 2018, 129, 122-126.	1.5	8
92	Toronto Clinical Neuropathy Score is valid for a wide spectrum of polyneuropathies. <i>European Journal of Neurology</i> , 2018, 25, 484-490.	3.3	23
93	Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Neurology</i> , The, 2018, 17, 35-46.	10.2	193
94	Diabetes Care Disparities in Long-standing Type 1 Diabetes in Canada and the U.S.: A Cross-sectional Comparison. <i>Diabetes Care</i> , 2018, 41, 88-95.	8.6	17
95	Peripheral neuropathy associated with imatinib therapy for chronic myeloid leukemia. <i>Blood Research</i> , 2018, 53, 172.	1.3	5
96	046â€¦Efficacy and safety of intravenous immunoglobulin (IVIg) IGPRO10 in chronic inflammatory demyelinating polyneuropathy (CIDP). <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, A19.2-A19.	1.9	0
97	Atherosclerosis and Microvascular Complications: Results From the Canadian Study of Longevity in Type 1 Diabetes. <i>Diabetes Care</i> , 2018, 41, 2570-2578.	8.6	37
98	The median to ulnar cross-sectional surface area ratio in carpal tunnel syndrome. <i>Clinical Neurophysiology</i> , 2018, 129, 2239-2244.	1.5	7
99	Sex differences in neuropathic pain in longstanding diabetes: Results from the Canadian Study of Longevity in Type 1 Diabetes. <i>Journal of Diabetes and Its Complications</i> , 2018, 32, 660-664.	2.3	22
100	Validation of a simple disease-specific, quality-of-life measure for diabetic polyneuropathy. <i>Neurology</i> , 2018, 90, e2034-e2041.	1.1	6
101	Corneal confocal microscopy for identification of diabetic sensorimotor polyneuropathy: a pooled multinational consortium study. <i>Diabetologia</i> , 2018, 61, 1856-1861.	6.3	103
102	Quantitative sonographic assessment of myotonia. <i>Muscle and Nerve</i> , 2018, 57, 146-149.	2.2	7
103	Renin-angiotensin-aldosterone system activation in long-standing type 1 diabetes. <i>JCI Insight</i> , 2018, 3, .	5.0	38
104	Validity of a point-of-care nerve conduction device for polyneuropathy identification in older adults with diabetes: Results from the Canadian Study of Longevity in Type 1 Diabetes. <i>PLoS ONE</i> , 2018, 13, e0196647.	2.5	13
105	Repetitive nerve stimulation cutoff values for the diagnosis of myasthenia gravis. <i>Muscle and Nerve</i> , 2017, 55, 166-170.	2.2	27
106	Peripheral nerve high-resolution ultrasound in diabetes. <i>Muscle and Nerve</i> , 2017, 55, 171-178.	2.2	64
107	Using in vivo corneal confocal microscopy to identify diabetic sensorimotor polyneuropathy risk profiles in patients with type 1 diabetes. <i>BMJ Open Diabetes Research and Care</i> , 2017, 5, e000251.	2.8	15
108	Selective or predominant triceps muscle weakness in African-American patients with myasthenia gravis. <i>Neuromuscular Disorders</i> , 2017, 27, 646-649.	0.6	6

#	ARTICLE	IF	CITATIONS
109	Effect of omega-3 supplementation on neuropathy in type 1 diabetes. <i>Neurology</i> , 2017, 88, 2294-2301.	1.1	95
110	Neuropathy and presence of emotional distress and depression in longstanding diabetes: Results from the Canadian study of longevity in type 1 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2017, 31, 1318-1324.	2.3	37
111	Uric acid levels correlate with the severity of diabetic sensorimotor polyneuropathy. <i>Journal of the Neurological Sciences</i> , 2017, 379, 94-98.	0.6	12
112	Diabetic Neuropathy: A Position Statement by the American Diabetes Association. <i>Diabetes Care</i> , 2017, 40, 136-154.	8.6	1,452
113	Electrophysiological testing is correlated with myasthenia gravis severity. <i>Muscle and Nerve</i> , 2017, 56, 445-448.	2.2	19
114	Clinical characteristics, and impairment and disability scale scores for different CIDP Disease Activity Status classes. <i>Journal of the Neurological Sciences</i> , 2017, 372, 223-227.	0.6	13
115	Neurofibromatosis Clinic: A Report on Patient Demographics and Evaluation of the Clinic. <i>Canadian Journal of Neurological Sciences</i> , 2017, 44, 577-588.	0.5	5
116	Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. <i>Lancet Neurology</i> , The, 2017, 16, 976-986.	10.2	472
117	Rare disease levels of evidence. <i>Neurology</i> , 2017, 89, 988-989.	1.1	0
118	High-Dose Subcutaneous Immunoglobulin in Patients With Multifocal Motor Neuropathy. <i>Journal of Infusion Nursing</i> , 2017, 40, 305-312.	2.3	8
119	Myasthenia Gravis Impairment Index. <i>Neurology</i> , 2017, 89, 2357-2364.	1.1	35
120	Recording Fewer Than 20 Potential Pairs With SFEMG May Suffice for the Diagnosis of Myasthenia Gravis. <i>Journal of Clinical Neurophysiology</i> , 2017, 34, 408-412.	1.7	5
121	Agreement between automated and manual quantification of corneal nerve fiber length: Implications for diabetic neuropathy research. <i>Journal of Diabetes and Its Complications</i> , 2017, 31, 1066-1073.	2.3	26
122	Gamunex® in Guillain-Barré Syndrome: A Postmarketing, Retrospective, Observational Study. <i>Canadian Journal of Neurological Sciences</i> , 2017, 44, 711-717.	0.5	2
123	Lower corneal nerve fibre length identifies diabetic neuropathy in older adults with diabetes: results from the Canadian Study of Longevity in Type 1 Diabetes. <i>Diabetologia</i> , 2017, 60, 2529-2531.	6.3	14
124	The sensitivity and specificity of the neurological examination in polyneuropathy patients with clinical and electrophysiological correlations. <i>PLoS ONE</i> , 2017, 12, e0171597.	2.5	21
125	Ultrasound in Neuromuscular Disorders. <i>Journal of Clinical Neurophysiology</i> , 2016, 33, 80-85.	1.7	13
126	International clinimetric evaluation of the MG-QOL15, resulting in slight revision and subsequent validation of the MG-QOL15r. <i>Muscle and Nerve</i> , 2016, 54, 1015-1022.	2.2	85

#	ARTICLE	IF	CITATIONS
127	Reference values for ultrasonography of peripheral nerves. <i>Muscle and Nerve</i> , 2016, 53, 538-544.	2.2	66
128	Study protocol for a pilot, randomised, double-blinded, placebo controlled trial of perineural local anaesthetics and steroids for chronic post-traumatic neuropathic pain in the ankle and foot: the PREPLANS study. <i>BMJ Open</i> , 2016, 6, e012293.	1.9	6
129	Prevalence of Insulin Pump Therapy and Its Association with Measures of Glycemic Control: Results from the Canadian Study of Longevity in Type 1 Diabetes. <i>Diabetes Technology and Therapeutics</i> , 2016, 18, 298-307.	4.4	25
130	Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (The PATH Study): study protocol for a randomized controlled trial. <i>Trials</i> , 2016, 17, 345.	1.6	21
131	The genomic landscape of schwannoma. <i>Nature Genetics</i> , 2016, 48, 1339-1348.	21.4	124
132	The Perfect Clinical Trial. <i>International Review of Neurobiology</i> , 2016, 127, 27-41.	2.0	7
133	Repetitive facial nerve stimulation in myasthenia gravis 1min after muscle activation is inferior to testing a second muscle at rest. <i>Clinical Neurophysiology</i> , 2016, 127, 3294-3297.	1.5	6
134	Disease activity in chronic inflammatory demyelinating polyneuropathy. <i>Journal of the Neurological Sciences</i> , 2016, 369, 204-209.	0.6	11
135	Development and validation of the Myasthenia Gravis Impairment Index. <i>Neurology</i> , 2016, 87, 879-886.	1.1	43
136	Infusing IVIG through Community Care Access Services in Patients with CIDP. <i>Canadian Journal of Neurological Sciences</i> , 2016, 43, 326-328.	0.5	0
137	Frequent laboratory abnormalities in CIDP patients. <i>Muscle and Nerve</i> , 2016, 53, 862-865.	2.2	18
138	Construction and validation of the chronic acquired polyneuropathy patient-reported index (CAPaPRI): A disease-specific, health-related quality-of-life instrument. <i>Muscle and Nerve</i> , 2016, 54, 9-17.	2.2	17
139	Subcutaneous immunoglobulin for treatment of multifocal motor neuropathy. <i>Muscle and Nerve</i> , 2016, 54, 856-863.	2.2	20
140	Cardiovascular disease guideline adherence and self-reported statin use in longstanding type 1 diabetes: results from the Canadian study of longevity in diabetes cohort. <i>Cardiovascular Diabetology</i> , 2016, 15, 14.	6.8	29
141	The dilemma of diabetes in chronic inflammatory demyelinating polyneuropathy. <i>Journal of Diabetes and Its Complications</i> , 2016, 30, 1401-1407.	2.3	43
142	Improving the management of chronic inflammatory demyelinating polyradiculoneuropathy. <i>Neurodegenerative Disease Management</i> , 2016, 6, 237-247.	2.2	2
143	A randomized controlled trial of methotrexate for patients with generalized myasthenia gravis. <i>Neurology</i> , 2016, 87, 57-64.	1.1	106
144	Cost-minimization analysis comparing intravenous immunoglobulin with plasma exchange in the management of patients with myasthenia gravis. <i>Muscle and Nerve</i> , 2016, 53, 872-876.	2.2	14

#	ARTICLE	IF	CITATIONS
145	Validation of cooling detection threshold as a marker of sensorimotor polyneuropathy in type 2 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2016, 30, 716-722.	2.3	20
146	Commonly Measured Clinical Variables Are Not Associated With Burden of Complications in Long-standing Type 1 Diabetes: Results From the Canadian Study of Longevity in Diabetes. <i>Diabetes Care</i> , 2016, 39, e67-e68.	8.6	19
147	Epidemiology of myasthenia gravis in Ontario, Canada. <i>Neuromuscular Disorders</i> , 2016, 26, 41-46.	0.6	90
148	Laser Doppler Flare Imaging and Quantitative Thermal Thresholds Testing Performance in Small and Mixed Fiber Neuropathies. <i>PLoS ONE</i> , 2016, 11, e0165731.	2.5	33
149	Gelsolin Familial Amyloidosis Peripheral Neuropathy in Canada: A Case Report. <i>Canadian Journal of Neurological Sciences</i> , 2015, 42, 353-355.	0.5	5
150	Comparing the <sc>NIS</sc> vs. <sc>MRC</sc> and <sc>INCAT</sc> sensory scale through Rasch analyses. <i>Journal of the Peripheral Nervous System</i> , 2015, 20, 277-288.	3.1	27
151	Grip strength comparison in immune-mediated neuropathies: Vigorimeter vs. Jamar. <i>Journal of the Peripheral Nervous System</i> , 2015, 20, 269-276.	3.1	28
152	Safety and efficacy of ranirestat in patients with mild-to-moderate diabetic sensorimotor polyneuropathy. <i>Journal of the Peripheral Nervous System</i> , 2015, 20, 363-371.	3.1	21
153	Impairment measures versus inflammatory <sc>RODS</sc> in <sc>GBS</sc> and <sc>CIDP</sc>: a responsiveness comparison. <i>Journal of the Peripheral Nervous System</i> , 2015, 20, 289-295.	3.1	30
154	Follow-up nerve conduction studies in CIDP after treatment with IGIV: Comparison of patients with and without subsequent relapse. <i>Muscle and Nerve</i> , 2015, 52, 498-502.	2.2	20
155	Psychometric Properties of the Quantitative Myasthenia Gravis Score and the Myasthenia Gravis Composite Scale. <i>Journal of Neuromuscular Diseases</i> , 2015, 2, 301-311.	2.6	11
156	Elevated Vibration Perception Thresholds in CIDP Patients Indicate More Severe Neuropathy and Lower Treatment Response Rates. <i>PLoS ONE</i> , 2015, 10, e0139689.	2.5	8
157	Reproducibility of In Vivo Corneal Confocal Microscopy Using an Automated Analysis Program for Detection of Diabetic Sensorimotor Polyneuropathy. <i>PLoS ONE</i> , 2015, 10, e0142309.	2.5	37
158	Peripheral Nerve Ultrasound in Small Fiber Polyneuropathy. <i>Ultrasound in Medicine and Biology</i> , 2015, 41, 2820-2826.	1.5	28
159	Diabetic Neuropathies. <i>Seminars in Neurology</i> , 2015, 35, 424-430.	1.4	21
160	Canadian Administrative Health Data Can Identify Patients with Myasthenia Gravis. <i>Neuroepidemiology</i> , 2015, 44, 108-113.	2.3	20
161	Treatment responsiveness in CIDP patients with diabetes is associated with unique electrophysiological characteristics, and not with common criteria for CIDP. <i>Expert Review of Clinical Immunology</i> , 2015, 11, 537-546.	3.0	13
162	Choosing drugs for the treatment of diabetic neuropathy. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 1805-1814.	1.8	6

#	ARTICLE	IF	CITATIONS
163	Normative Values for Corneal Nerve Morphology Assessed Using Corneal Confocal Microscopy: A Multinational Normative Data Set. <i>Diabetes Care</i> , 2015, 38, 838-843.	8.6	150
164	In Vivo Corneal Confocal Microscopy and Prediction of Future Incident Neuropathy in Type 1 Diabetes: A Preliminary Longitudinal Analysis. <i>Canadian Journal of Diabetes</i> , 2015, 39, 390-397.	0.8	57
165	Treatment Responsiveness in CIDP Patients with Diabetes Is Associated with Higher Degrees of Demyelination. <i>PLoS ONE</i> , 2015, 10, e0139674.	2.5	9
166	Excessive Daytime Sleepiness in Patients with Myasthenia Gravis. <i>Journal of Neuromuscular Diseases</i> , 2015, 2, 93-97.	2.6	1
167	Reliability and Validity of a Point-of-Care Sural Nerve Conduction Device for Identification of Diabetic Neuropathy. <i>PLoS ONE</i> , 2014, 9, e86515.	2.5	72
168	The Characteristics of Chronic Inflammatory Demyelinating Polyneuropathy in Patients with and without Diabetes – An Observational Study. <i>PLoS ONE</i> , 2014, 9, e89344.	2.5	29
169	Intravenous immunoglobulin as treatment for myasthenia gravis: current evidence and outcomes. <i>Expert Review of Clinical Immunology</i> , 2014, 10, 1659-1665.	3.0	31
170	Prevalence of Muscle Cramps in Patients With Diabetes: Table 1. <i>Diabetes Care</i> , 2014, 37, e17-e18.	8.6	21
171	Response to Comment on Breiner et al. Does the Prevailing Hypothesis That Small-Fiber Dysfunction Precedes Large-Fiber Dysfunction Apply to Type 1 Diabetic Patients? <i>Diabetes Care</i> 2014;37:1418-1424. <i>Diabetes Care</i> , 2014, 37, e242-e242.	8.6	1
172	Does the Prevailing Hypothesis That Small-Fiber Dysfunction Precedes Large-Fiber Dysfunction Apply to Type 1 Diabetic Patients?. <i>Diabetes Care</i> , 2014, 37, 1418-1424.	8.6	105
173	Changing outcome in inflammatory neuropathies. <i>Neurology</i> , 2014, 83, 2124-2132.	1.1	89
174	Thymectomy for non-thymomatous myasthenia gravis: a propensity score matched study. <i>Orphanet Journal of Rare Diseases</i> , 2014, 9, 214.	2.7	26
175	Neuromuscular Complications of Diabetes Mellitus. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2014, 20, 531-544.	0.8	12
176	Characteristics of muscle cramps in patients with polyneuropathy. <i>Neuromuscular Disorders</i> , 2014, 24, 671-676.	0.6	8
177	Comparison of monoclonal gammopathy of undetermined significance-associated neuropathy and chronic inflammatory demyelinating polyneuropathy patients. <i>Journal of Neurology</i> , 2014, 261, 1485-1491.	3.6	13
178	Incat disability score: A critical analysis of its measurement properties. <i>Muscle and Nerve</i> , 2014, 50, 164-169.	2.2	41
179	Electrophysiologic testing in diabetic neuropathy. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2014, 126, 235-248.	1.8	32
180	Minimal clinically important difference in myasthenia gravis: Outcomes from a randomized trial. <i>Muscle and Nerve</i> , 2014, 49, 661-665.	2.2	50

#	ARTICLE	IF	CITATIONS
181	Ischaemia due to a vascular malformation causing focal myositis. <i>BMJ Case Reports</i> , 2014, 2014, bcr2013202442-bcr2013202442.	0.5	5
182	A Conceptual Framework for Evaluating Impairments in Myasthenia Gravis. <i>PLoS ONE</i> , 2014, 9, e98089.	2.5	23
183	Measurement of Cooling Detection Thresholds for Identification of Diabetic Sensorimotor Polyneuropathy in Type 1 Diabetes. <i>PLoS ONE</i> , 2014, 9, e106995.	2.5	14
184	Performance of individual items of the quantitative myasthenia gravis score. <i>Neuromuscular Disorders</i> , 2013, 23, 413-417.	0.6	18
185	Conduction Slowing in Diabetic Sensorimotor Polyneuropathy. <i>Diabetes Care</i> , 2013, 36, 3684-3690.	8.6	63
186	The impact of common variation in the definition of diabetic sensorimotor polyneuropathy on the validity of corneal in vivo confocal microscopy in patients with type 1 diabetes: a brief report. <i>Journal of Diabetes and Its Complications</i> , 2013, 27, 240-242.	2.3	15
187	Neuropathy. <i>Canadian Journal of Diabetes</i> , 2013, 37, S142-S144.	0.8	19
188	Diagnosis of Painful Diabetic Neuropathy. , 2013, , 27-34.		0
189	Safety of plasma exchange therapy in patients with myasthenia gravis. <i>Muscle and Nerve</i> , 2013, 47, 510-514.	2.2	32
190	Changes in quality of life scores with intravenous immunoglobulin or plasmapheresis in patients with myasthenia gravis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2013, 84, 94-97.	1.9	28
191	Association of social support with quality of life in patients with polyneuropathy. <i>Journal of the Peripheral Nervous System</i> , 2013, 18, 37-43.	3.1	10
192	Comparison of diabetes patients with demyelinating diabetic sensorimotor polyneuropathy to those diagnosed with CIDP. <i>Brain and Behavior</i> , 2013, 3, 656-663.	2.2	21
193	Structure-Function Relationship Between Corneal Nerves and Conventional Small-Fiber Tests in Type 1 Diabetes. <i>Diabetes Care</i> , 2013, 36, 2748-2755.	8.6	83
194	Identification and Prediction of Diabetic Sensorimotor Polyneuropathy Using Individual and Simple Combinations of Nerve Conduction Study Parameters. <i>PLoS ONE</i> , 2013, 8, e58783.	2.5	58
195	Detection of Diabetic Sensorimotor Polyneuropathy by Corneal Confocal Microscopy in Type 1 Diabetes. <i>Diabetes Care</i> , 2012, 35, 821-828.	8.6	177
196	Fcγ3 Receptor Polymorphisms Do Not Predict Response to Intravenous Immunoglobulin in Myasthenia Gravis. <i>Journal of Clinical Neuromuscular Disease</i> , 2012, 14, 1-6.	0.7	3
197	The Quantitative Myasthenia Gravis Score. <i>Journal of Clinical Neuromuscular Disease</i> , 2012, 13, 201-205.	0.7	46
198	Variables associated with corneal confocal microscopy parameters in healthy volunteers: implications for diabetic neuropathy screening. <i>Diabetic Medicine</i> , 2012, 29, e297-303.	2.3	62

#	ARTICLE	IF	CITATIONS
199	Can Ultrasound of the Tibial Nerve Detect Diabetic Peripheral Neuropathy?. <i>Diabetes Care</i> , 2012, 35, 2575-2579.	8.6	92
200	Higher magnification lenses versus conventional lenses for evaluation of diabetic neuropathy by corneal in vivo confocal microscopy. <i>Diabetes Research and Clinical Practice</i> , 2012, 97, e37-e40.	2.8	12
201	IVIg and PLEX in the treatment of myasthenia gravis. <i>Annals of the New York Academy of Sciences</i> , 2012, 1275, 1-6.	3.8	21
202	Diabetic Neuropathy and Axon Reflex-Mediated Neurogenic Vasodilatation in Type 1 Diabetes. <i>PLoS ONE</i> , 2012, 7, e34807.	2.5	22
203	Predictors of response to immunomodulation in patients with myasthenia gravis. <i>Muscle and Nerve</i> , 2012, 45, 648-652.	2.2	18
204	Treatments for diabetic neuropathy. <i>Journal of the Peripheral Nervous System</i> , 2012, 17, 22-27.	3.1	54
205	Suralâ€™radial amplitude ratio in the diagnosis of diabetic sensorimotor polyneuropathy. <i>Muscle and Nerve</i> , 2012, 45, 126-127.	2.2	15
206	Evaluation of Proxy Tests for SFSN: Evidence for Mixed Small and Large Fiber Dysfunction. <i>PLoS ONE</i> , 2012, 7, e42208.	2.5	14
207	How sensitive is the case definition for diabetic sensorimotor polyneuropathy to the use of different symptoms, signs, and nerve conduction parameters in Type 1 diabetes?. <i>Diabetes Research and Clinical Practice</i> , 2011, 92, e16-e19.	2.8	6
208	Dorsal versus ventral monofilament testing of the great toe for the identification of diabetic sensorimotor polyneuropathy. <i>Diabetes Research and Clinical Practice</i> , 2011, 93, e71-e73.	2.8	3
209	Reproducibility of in vivo corneal confocal microscopy as a novel screening test for early diabetic sensorimotor polyneuropathy. <i>Diabetic Medicine</i> , 2011, 28, 1253-1260.	2.3	135
210	Diabetic polyneuropathies: update on research definition, diagnostic criteria and estimation of severity. <i>Diabetes/Metabolism Research and Reviews</i> , 2011, 27, 620-628.	4.0	359
211	Comparison of IVIg and PLEX in patients with myasthenia gravis. <i>Neurology</i> , 2011, 76, 2017-2023.	1.1	273
212	Evidence-based guideline: Treatment of painful diabetic neuropathy [RETIRED]. <i>Neurology</i> , 2011, 76, 1758-1765.	1.1	561
213	Electrophysiologic correlations with clinical outcomes in CIDP. <i>Muscle and Nerve</i> , 2010, 42, 492-497.	2.2	56
214	Understanding the consequences of chronic inflammatory demyelinating polyradiculoneuropathy from impairments to activity and participation restrictions and reduced quality of life: the ICE study. <i>Journal of the Peripheral Nervous System</i> , 2010, 15, 208-215.	3.1	41
215	Shortâ€™term metabolic change is associated with improvement in measures of diabetic neuropathy: a 1â€™year placebo cohort analysis. <i>Diabetic Medicine</i> , 2010, 27, 1271-1279.	2.3	27
216	Prediction of Incident Diabetic Neuropathy Using the Monofilament Examination. <i>Diabetes Care</i> , 2010, 33, 1549-1554.	8.6	80

#	ARTICLE	IF	CITATIONS
217	Timing and Course of Clinical Response to Intravenous Immunoglobulin in Chronic Inflammatory Demyelinating Polyradiculoneuropathy. <i>Archives of Neurology</i> , 2010, 67, 802.	4.5	99
218	Ranirestat for the Management of Diabetic Sensorimotor Polyneuropathy. <i>Diabetes Care</i> , 2009, 32, 1256-1260.	8.6	88
219	Current and future immunotherapy in myasthenia gravis. <i>Future Neurology</i> , 2009, 4, 745-759.	0.5	1
220	Electrophysiology in chronic inflammatory demyelinating polyneuropathy with IGIV. <i>Muscle and Nerve</i> , 2009, 39, 448-455.	2.2	42
221	Reliability and validity of the modified Toronto Clinical Neuropathy Score in diabetic sensorimotor polyneuropathy. <i>Diabetic Medicine</i> , 2009, 26, 240-246.	2.3	153
222	Improvement of Motor Nerve Conduction Velocity in Diabetic Rats Requires Normalization of the Polyol Pathway Metabolites Flux. <i>Journal of Pharmacological Sciences</i> , 2009, 109, 203-210.	2.5	12
223	Surrogate therapeutic outcome measures in patients with myasthenia gravis. <i>Muscle and Nerve</i> , 2008, 37, 172-176.	2.2	12
224	IVIg Treatment for Myasthenia Gravis. <i>Annals of the New York Academy of Sciences</i> , 2008, 1132, 264-270.	3.8	23
225	Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. <i>Lancet Neurology</i> , 2008, 7, 136-144.	10.2	582
226	Ranirestat (AS-3201), a Potent Aldose Reductase Inhibitor, Reduces Sorbitol Levels and Improves Motor Nerve Conduction Velocity in Streptozotocin-Diabetic Rats. <i>Journal of Pharmacological Sciences</i> , 2008, 107, 231-237.	2.5	41
227	Long-Term Treatment With Ranirestat (AS-3201), a Potent Aldose Reductase Inhibitor, Suppresses Diabetic Neuropathy and Cataract Formation in Rats. <i>Journal of Pharmacological Sciences</i> , 2008, 107, 340-348.	2.5	39
228	A Comparison of the Effectiveness of Intravenous Immunoglobulin and Plasma Exchange as Preoperative Therapy of Myasthenia Gravis. <i>Journal of Clinical Neuromuscular Disease</i> , 2008, 9, 352-355.	0.7	44
229	IV immunoglobulin in patients with myasthenia gravis. <i>Neurology</i> , 2007, 68, 837-841.	1.1	255
230	Management of Myasthenia Gravis: Does Thymectomy Provide Benefit over Medical Therapy Alone?. <i>Neurology</i> , 2007, 68, 463-468.		0
231	Sensitivity of repetitive facial nerve stimulation in patients with myasthenia gravis. <i>Muscle and Nerve</i> , 2006, 33, 694-696.	2.2	28
232	Diagnostic Tools for Diabetic Sensorimotor Polyneuropathy. <i>Current Diabetes Reviews</i> , 2006, 2, 353-361.	1.3	9
233	Long-Term Effects of Ranirestat (AS-3201) on Peripheral Nerve Function in Patients With Diabetic Sensorimotor Polyneuropathy. <i>Diabetes Care</i> , 2006, 29, 68-72.	8.6	126
234	Validation of a Novel Point-of-Care Nerve Conduction Device for the Detection of Diabetic Sensorimotor Polyneuropathy. <i>Diabetes Care</i> , 2006, 29, 2023-2027.	8.6	53

#	ARTICLE	IF	CITATIONS
235	A Comparison of Electrodiagnostic Tests in Ocular Myasthenia Gravis. <i>Journal of Clinical Neuromuscular Disease</i> , 2005, 6, 109-113.	0.7	28
236	Sural sensory action potential identifies diabetic peripheral neuropathy responders to therapy. <i>Muscle and Nerve</i> , 2005, 32, 619-625.	2.2	56
237	Emerging Therapies for Diabetic Neuropathy: A Clinical Overview. <i>Current Diabetes Reviews</i> , 2005, 1, 271-280.	1.3	11
238	Treatment of symptomatic diabetic peripheral neuropathy with the protein kinase C $\hat{2}$ -inhibitor ruboxistaurin mesylate during a 1-year, randomized, placebo-controlled, double-blind clinical trial. <i>Clinical Therapeutics</i> , 2005, 27, 1164-1180.	2.5	161
239	Development and validity testing of the neuropathy total symptom score-6: Questionnaire for the study of sensory symptoms of diabetic peripheral neuropathy. <i>Clinical Therapeutics</i> , 2005, 27, 1278-1294.	2.5	162
240	A pilot study to compare the use of the Excorim staphylococcal protein immunoabsorption system and IVIG in chronic inflammatory demyelinating polyneuropathy. <i>Transfusion and Apheresis Science</i> , 2005, 33, 317-324.	1.0	30
241	Diabetic Neuropathies. <i>Diabetes Care</i> , 2005, 28, 956-962.	8.6	1,599
242	Low-Intensity Laser Therapy for Painful Symptoms of Diabetic Sensorimotor Polyneuropathy: A controlled trial. <i>Diabetes Care</i> , 2004, 27, 921-924.	8.6	69
243	Sural Nerve Sorbitol in Patients With Diabetic Sensorimotor Polyneuropathy. <i>Diabetes Care</i> , 2004, 27, 1160-1163.	8.6	12
244	Aldose Reductase Inhibition by AS-3201 in Sural Nerve From Patients With Diabetic Sensorimotor Polyneuropathy. <i>Diabetes Care</i> , 2004, 27, 2369-2375.	8.6	88
245	Cooling Detection Thresholds in the Assessment of Diabetic Sensory Polyneuropathy: Comparison of CASE IV and Medoc instruments. <i>Diabetes Care</i> , 2004, 27, 1674-1679.	8.6	42
246	Diabetic neuropathy: a review emphasizing diagnostic methods. <i>Clinical Neurophysiology</i> , 2003, 114, 1167-1175.	1.5	139
247	Impact of minimally invasive trans-cervical thymectomy on outcome in patients with myasthenia gravis. <i>European Journal of Cardio-thoracic Surgery</i> , 2003, 24, 677-683.	1.4	81
248	Validation of the Toronto Clinical Scoring System for Diabetic Polyneuropathy. <i>Diabetes Care</i> , 2002, 25, 2048-2052.	8.6	341
249	Comparison of sensory testing on different toe surfaces: Implications for neuropathy screening. <i>Neurology</i> , 2002, 59, 611-613.	1.1	24
250	Carpal Tunnel Syndrome in Patients With Diabetic Polyneuropathy. <i>Diabetes Care</i> , 2002, 25, 565-569.	8.6	241
251	Prognostic significance of thymomas in patients with myasthenia gravis. <i>Annals of Thoracic Surgery</i> , 2002, 74, 1658-1662.	1.3	66
252	Symmetry of nerve conduction studies in different stages of diabetic polyneuropathy. <i>Muscle and Nerve</i> , 2002, 25, 212-217.	2.2	28

#	ARTICLE	IF	CITATIONS
253	Diagnosis and management of diabetic neuropathy. <i>Current Diabetes Reports</i> , 2002, 2, 495-500.	4.2	32
254	Comparison of vibration perception thresholds obtained with the Neurothesiometer and the CASE IV and relationship to nerve conduction studies. <i>Diabetic Medicine</i> , 2002, 19, 661-666.	2.3	46
255	Evaluation of three screening tests and a risk assessment model for diagnosing peripheral neuropathy in the diabetes clinic. <i>Diabetes Research and Clinical Practice</i> , 2001, 54, 115-128.	2.8	123
256	Status of Current Clinical Trials in Diabetic Polyneuropathy. <i>Canadian Journal of Neurological Sciences</i> , 2001, 28, 191-198.	0.5	18
257	Simple Screening Tests for Peripheral Neuropathy in the Diabetes Clinic. <i>Diabetes Care</i> , 2001, 24, 250-256.	8.6	454
258	Glycemic Control Is Related to the Morphological Severity of Diabetic Sensorimotor Polyneuropathy. <i>Diabetes Care</i> , 2001, 24, 748-752.	8.6	54
259	Heart Rate Variability Measurement in Diabetic Neuropathy: Review of Methods. <i>Diabetes Technology and Therapeutics</i> , 2001, 3, 63-76.	4.4	59
260	Sensory nerve area measurements in patients with diabetic neuropathy. <i>Electromyography and Clinical Neurophysiology</i> , 2001, 41, 59-63.	0.2	1
261	Impact of plasma exchange on indices of demyelination in chronic inflammatory demyelinating polyradiculoneuropathy. <i>Muscle and Nerve</i> , 2000, 23, 206-210.	2.2	21
262	Limits of the sympathetic skin response in patients with diabetic polyneuropathy. <i>Muscle and Nerve</i> , 2000, 23, 1427-1430.	2.2	26
263	NIS-LL: The Primary Measurement Scale for Clinical Trial Endpoints in Diabetic Peripheral Neuropathy. <i>European Neurology</i> , 1999, 41, 8-13.	1.4	120
264	Electrophysiological monitoring in clinical trials. , 1998, 21, 1368-1373.		95
265	Long-Term Clinical Outcome After Transcervical Thymectomy for Myasthenia Gravis. <i>Annals of Thoracic Surgery</i> , 1998, 65, 1520-1522.	1.3	96
266	The long-term clinical outcome of myasthenia gravis in patients with thymoma. <i>Neurology</i> , 1998, 51, 1198-1200.	1.1	39
267	Glycemic Control Is Related to the Electrophysiologic Severity of Diabetic Peripheral Sensorimotor Polyneuropathy. <i>Diabetes Care</i> , 1998, 21, 1749-1752.	8.6	49
268	Comparison of a Neurothesiometer and Vibration in Measuring Vibration Perception Thresholds and Relationship to Nerve Conduction Studies. <i>Diabetes Care</i> , 1997, 20, 1360-1362.	8.6	50
269	POEMS syndrome in a 24-year-old man associated with vitamin B12 deficiency and a solitary lytic bone lesion. , 1997, 20, 1454-1456.		6
270	Single-fiber electromyography in diabetic peripheral polyneuropathy. , 1996, 19, 2-9.		52

#	ARTICLE	IF	CITATIONS
271	Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy: A double-blind, sham-controlled, cross-over study. <i>Brain</i> , 1996, 119, 1055-1066.	7.6	392
272	Components of variance for vibratory and thermal threshold testing in normal and diabetic subjects. <i>Journal of Diabetes and Its Complications</i> , 1995, 9, 170-176.	2.3	73
273	Complications of Sural Nerve Biopsy in Diabetic versus Non-Diabetic Patients. <i>Canadian Journal of Neurological Sciences</i> , 1994, 21, 34-37.	0.5	38
274	Role of Electrophysiological Studies in Diabetic Neuropathy. <i>Canadian Journal of Neurological Sciences</i> , 1994, 21, S8-S12.	0.5	28
275	Congenital myasthenic syndromes: II. Syndrome attributed to abnormal interaction of acetylcholine with its receptor. <i>Muscle and Nerve</i> , 1993, 16, 1293-1301.	2.2	68
276	Regeneration and Repair of Myelinated Fibers in Sural-Nerve Biopsy Specimens from Patients with Diabetic Neuropathy Treated with Sorbinil. <i>New England Journal of Medicine</i> , 1988, 319, 548-555.	27.0	321
277	Histopathological heterogeneity of neuropathy in insulin-dependent and non-insulin-dependent diabetes, and demonstration of axo-glial dysjunction in human diabetic neuropathy.. <i>Journal of Clinical Investigation</i> , 1988, 81, 349-364.	8.2	197
278	Midbrain asterix. <i>Annals of Neurology</i> , 1979, 6, 362-364.	5.3	41
279	Gastrointestinal Dysmotility as the First Manifestation of Myasthenia Gravis. <i>Canadian Journal of Neurological Sciences</i> , 0, , 1-7.	0.5	0